{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:54:08Z","timestamp":1792144448774,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.phrs.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T04:53:08Z","timestamp":1438836788000},"page":"157-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Transcriptional dysregulation in Huntington\u2019s disease: The role of histone deacetylases"],"prefix":"10.1016","volume":"100","author":[{"given":"Sorabh","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Taliyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.08.002_bib0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2015.08.002_bib0010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.phrs.2015.08.002_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"issue":"5334","key":"10.1016\/j.phrs.2015.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.phrs.2015.08.002_bib0025","doi-asserted-by":"crossref","first-page":"e14311","DOI":"10.1371\/journal.pone.0014311","article-title":"Transcriptional activation of REST by Sp1 in Huntington\u2019s disease models","volume":"5","author":"Ravache","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2015.08.002_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.59566\/IJBS.2011.7089","article-title":"Huntington\u2019s disease: from mutant huntingtin protein to neurotrophic factor therapy","volume":"7","author":"Sari","year":"2011","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fneur.2013.00127","article-title":"Multiple aspects of gene dysregulation in Huntington\u2019s disease","volume":"4","author":"Moumn\u00e9","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington\u2019s disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.brainresbull.2011.07.021","article-title":"Gene expression and behaviour in mouse models of HD","volume":"88","author":"Bowles","year":"2012","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2015.08.002_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2011.07.001","article-title":"What have we learnt from gene expression profiles in Huntington\u2019s disease","volume":"45","author":"Seredenina","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2015.08.002_bib0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington\u2019s disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/13816128113199990355","article-title":"Histone post-translational modifications in Huntington\u2019s and Parkinson\u2019s diseases","volume":"19","author":"Pena-Altamira","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2015.08.002_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/303294","article-title":"Targeting histone deacetylases: a novel approach in Parkinson\u2019s disease","volume":"2015","author":"Sharma","year":"2015","journal-title":"Parkinson\u2019s Dis."},{"issue":"24","key":"10.1016\/j.phrs.2015.08.002_bib0070","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1093\/emboj\/cdg615","article-title":"Critical loss of CBP\/p300 histone acetylase activity by caspase-6 during neurodegeneration","volume":"22","author":"Rouaux","year":"2003","journal-title":"EMBO J."},{"issue":"20","key":"10.1016\/j.phrs.2015.08.002_bib0075","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12031-014-0461-x","article-title":"Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice","volume":"56","author":"Sharma","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2015.08.002_bib0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00210-014-1081-2","article-title":"Synergistic effects of GSK-3\u03b2 and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats, Naunyn Schmiedeberg\u2019s","volume":"388","author":"Sharma","year":"2015","journal-title":"Arch. Pharmacol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2015.05.052","article-title":"Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioural abnormalities: modulation of histone deacetylase activity","volume":"291","author":"Sharma","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"6857","key":"10.1016\/j.phrs.2015.08.002_bib0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2015.08.002_bib0100","doi-asserted-by":"crossref","first-page":"e41423","DOI":"10.1371\/journal.pone.0041423","article-title":"Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington\u2019s disease","volume":"7","author":"McFarland","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2015.08.002_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10585-007-9131-5","article-title":"Histone deacetylases: target enzymes for cancer therapy","volume":"25","author":"Mottet","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/acn3.147","article-title":"The promise and perils of HDAC inhibitors in neurodegeneration","volume":"2","author":"Didonna","year":"2015","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0120","first-page":"153","article-title":"Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease","volume":"12","author":"Wang","year":"2015","journal-title":"J. Geriatric Cardiol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02686117","article-title":"Distribution of histone deacetylases 1\u201311 in the rat brain","volume":"31","author":"Broide","year":"2007","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-8-243","article-title":"Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas","volume":"8","author":"Lucio-Eterovic","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2015.08.002_bib0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12975-011-0087-z","article-title":"Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia","volume":"2","author":"Baltan","year":"2011","journal-title":"Trans. Stroke Res."},{"key":"10.1016\/j.phrs.2015.08.002_bib0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/NEN.0b013e3181ddd404","article-title":"Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis","volume":"69","author":"Janssen","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0145","doi-asserted-by":"crossref","first-page":"15254","DOI":"10.1074\/jbc.M908988199","article-title":"Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor","volume":"275","author":"Hu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0150","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","article-title":"Three proteins define a class of human histone deacetylases related to yeast Hda1p","volume":"96","author":"Grozinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0155","doi-asserted-by":"crossref","first-page":"9544","DOI":"10.1523\/JNEUROSCI.1826-05.2005","article-title":"Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death","volume":"25","author":"Bolger","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nn1659","article-title":"Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action","volume":"9","author":"Tsankova","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2015.08.002_bib0165","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","article-title":"Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington\u2019s disease","volume":"4","author":"Benn","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0170","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0175","first-page":"31","article-title":"HDAC9 is implicated in schizophrenia and expressed specifically in post-mitotic neurons but not in adult neural stem cells","volume":"1","author":"Lang","year":"2011","journal-title":"Am. J. Stem Cells"},{"key":"10.1016\/j.phrs.2015.08.002_bib0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11064-006-9127-6","article-title":"Microtubule deacetylases, SirT2 and HDAC6, in the nervous system","volume":"32","author":"Southwood","year":"2007","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.phrs.2015.08.002_bib0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1074\/jbc.M108931200","article-title":"Isolation and characterization of mammalian HDAC10, a novel histone deacetylase","volume":"277","author":"Kao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2014.00333","article-title":"Differential expression of sirtuin family members in the developing, adult, and aged rat brain","volume":"6","author":"Sidorova-Darmos","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0195","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0200","first-page":"RN1172","article-title":"Evaluation of histone deacetylases as drug targets in Huntington\u2019s disease models. Study of HDACs in brain tissues from R6\/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model","author":"Quinti","year":"2010","journal-title":"PLoS Curr."},{"issue":"42","key":"10.1016\/j.phrs.2015.08.002_bib0205","doi-asserted-by":"crossref","first-page":"35444","DOI":"10.1074\/jbc.M112.394544","article-title":"Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death","volume":"287","author":"Bardai","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0210","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","article-title":"Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease","volume":"46","author":"Jia","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2015.08.002_bib0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1471-4159.2003.01991.x","article-title":"Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein","volume":"87","author":"Hoshino","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.08.002_bib0230","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1523\/JNEUROSCI.5704-10.2011","article-title":"Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3","volume":"31","author":"Bardai","year":"2011","journal-title":"J. Neurosci."},{"issue":"29","key":"10.1016\/j.phrs.2015.08.002_bib0235","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1523\/JNEUROSCI.5831-12.2013","article-title":"Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity","volume":"33","author":"Bardai","year":"2013","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.phrs.2015.08.002_bib0240","doi-asserted-by":"crossref","first-page":"e111277","DOI":"10.1371\/journal.pone.0111277","article-title":"Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates","volume":"9","author":"Mano","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0245","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","article-title":"Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington\u2019s disease","volume":"7","author":"Moumn\u00e9","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0250","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","article-title":"Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy","volume":"35","author":"Katsuno","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2015.08.002_bib0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)81781-X","article-title":"Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice","volume":"95","author":"Klement","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.08.002_bib0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2377-12-47","article-title":"Huntington\u2019s disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database","volume":"12","author":"Kalathur","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fncel.2015.00042","article-title":"HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements","volume":"9","author":"Mielcarek","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0270","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington\u2019s disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0275","first-page":"2547","article-title":"Cardiac dysfunction in Huntington\u2019s disease","volume":"20","author":"Zielonka","year":"2014","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0280","doi-asserted-by":"crossref","first-page":"e1004550","DOI":"10.1371\/journal.pgen.1004550","article-title":"Dysfunction of the CNS-heart axis in mouse models of Huntington\u2019s disease","volume":"10","author":"Mielcarek","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0285","doi-asserted-by":"crossref","first-page":"e108961","DOI":"10.1371\/journal.pone.0108961","article-title":"The Huntington\u2019s disease-related cardiomyopathy prevents a hypertrophic response in the R6\/2 mouse model","volume":"9","author":"Mielcarek","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainres.2013.02.012","article-title":"Histone deacetylases class II and acetylated core histone immunohisto-chemistry in human brains with Huntington\u2019s disease","volume":"1504","author":"Yeh","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2015.08.002_bib0295","doi-asserted-by":"crossref","first-page":"e1001717","DOI":"10.1371\/journal.pbio.1001717","article-title":"HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration","volume":"11","author":"Mielcarek","year":"2013","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.phrs.2015.08.002_bib0300","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","article-title":"Hdac6 knockout increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington\u2019s disease","volume":"6","author":"Bobrowska","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0305","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/ml4002216","article-title":"Histone deacetylases 4 (HDAC4) inhibitors: a promising treatment for Huntington\u2019s disease","volume":"4","author":"Ahmed","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2015.08.002_bib0310","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1021\/jm4009295","article-title":"Foundation-directed therapeutic development in Huntington\u2019s disease","volume":"57","author":"Dominguez","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0315","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11033-013-2891-x","article-title":"MicroRNA-22 targeting CBP protects against myocardial ischemia-reperfusion injury through anti-apoptosis in rats","volume":"41","author":"Yang","year":"2014","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2010.10.012","article-title":"Altered microRNA regulation in Huntington\u2019s disease models","volume":"227","author":"Lee","year":"2011","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0325","doi-asserted-by":"crossref","first-page":"e54222","DOI":"10.1371\/journal.pone.0054222","article-title":"MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington\u2019s disease-related mechanisms","volume":"8","author":"Jovicic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0330","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1523\/JNEUROSCI.4278-06.2007","article-title":"Widespread disruption of repressor Element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease","volume":"27","author":"Zuccato","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0335","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1128\/MCB.21.23.8035-8044.2001","article-title":"Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways","volume":"21","author":"Seigneurin-Berny","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0340","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.08.002_bib0345","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumour activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Simoes-Pires","year":"2013","journal-title":"Mol. Neurodegener"},{"key":"10.1016\/j.phrs.2015.08.002_bib0355","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M508786200","article-title":"HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin","volume":"280","author":"Iwata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0360","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington\u2019s disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0365","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/1535-7163.MCT-07-0251","article-title":"Histone deacetylase inhibitors selectively suppress expression of HDAC7","volume":"6","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.phrs.2015.08.002_bib0370","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1074\/jbc.M110.146860","article-title":"Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism","volume":"286","author":"Ma","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2006.07.002","article-title":"Sirtuins in aging and age-related disease","volume":"126","author":"Longo","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2015.08.002_bib0380","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1523\/JNEUROSCI.3257-08.2008","article-title":"Brain SIRT1: anatomical distribution and regulation by energy availability","volume":"28","author":"Ramadori","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0385","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.M609554200","article-title":"Nucleocytoplasmic shuttling of the NAD\u00fe-dependent histone deacetylases SIRT1","volume":"282","author":"Tanno","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0390","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng1534","article-title":"Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons","volume":"37","author":"Parker","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.abb.2011.04.002","article-title":"Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation","volume":"510","author":"Sorolla","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.phrs.2015.08.002_bib0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","article-title":"Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease","volume":"225","author":"Ho","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0405","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","article-title":"Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway","volume":"18","author":"Jeong","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2015.08.002_bib0410","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","article-title":"Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets","volume":"18","author":"Jiang","year":"2012","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.phrs.2015.08.002_bib0415","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/acn3.135","article-title":"Sirtuin 1 activator SRT2104 protects Huntington\u2019s disease mice","volume":"1","author":"Jiang","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"11","key":"10.1016\/j.phrs.2015.08.002_bib0420","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","article-title":"A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington\u2019s disease","volume":"23","author":"Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2015.08.002_bib0425","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","article-title":"An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease","volume":"79","author":"Sussmuth","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0430","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington\u2019s disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0435","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1073\/pnas.1002924107","article-title":"SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis","volume":"107","author":"Luthi-Carter","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0440","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/cb100376q","article-title":"A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase","author":"Taylor","year":"2011","journal-title":"ACS Chem. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2015.08.002_bib0445","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.celrep.2012.11.001","article-title":"The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington\u2019s disease mouse models","volume":"2","author":"Chopra","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2015.08.002_bib0450","doi-asserted-by":"crossref","first-page":"e34805","DOI":"10.1371\/journal.pone.0034805","article-title":"SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington\u2019s disease phenotypes in vivo","volume":"7","author":"Bobrowska","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0455","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0460","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","article-title":"Transcription, epigenetics and ameliorative strategies in Huntington\u2019s disease: a genome-wide perspective","volume":"51","author":"Valor","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2015.04.009","article-title":"Epigenetic based therapies in the preclinical and clinical treatment of Huntington\u2019s disease","author":"Valor","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0470","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuropharm.2013.10.025","article-title":"What's wrong with epigenetics in Huntington\u2019s disease","volume":"80","author":"Valor","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2015.08.002_bib0475","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1755-5949.2010.00184.x","article-title":"Targeting histone deacetylases for the treatment of Huntington\u2019s disease","volume":"16","author":"Gray","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.phrs.2015.08.002_bib0480","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13148-011-0025-7","article-title":"Targeting Huntington\u2019s disease through histone deacetylases","volume":"2","author":"Gray","year":"2011","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0485","first-page":"137","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004"},{"key":"10.1016\/j.phrs.2015.08.002_bib0490","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.20372","article-title":"Histone deacetylase inhibitors: understanding a new wave of anticancer agents","volume":"112","author":"Villar-Garea","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2015.08.002_bib0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-4598-2-21","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2015.08.002_bib0500","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.08.002_bib0505","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0510","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tins.2009.06.002","article-title":"Multiple roles of HDAC inhibition in neurodegenerative conditions","volume":"32","author":"Chuang","year":"2009","journal-title":"Trends Neurosci."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2015.08.002_bib0515","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","article-title":"Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy","volume":"1","author":"Wagner","year":"2010","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0520","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/mol.109.061333","article-title":"Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?","volume":"77","author":"Grayson","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0525","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2015.08.002_bib0530","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jm0303655","article-title":"Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors","volume":"47","author":"Lu","year":"2003","journal-title":"J. Med. Chem."},{"issue":"40","key":"10.1016\/j.phrs.2015.08.002_bib0535","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0540","first-page":"4916","article-title":"FK228 (Depsipeptide) as a natural prodrug that inhibits class i histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2015.08.002_bib0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2015.08.002_bib0550","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1358\/dot.2009.45.11.1437052","article-title":"Romidepsin for the treatment of cutaneous T-cell lymphoma","volume":"45","author":"Campas-Moya","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.phrs.2015.08.002_bib0555","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteinsmodulates cellular signalling atmultiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0565","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cmdc.200700003","article-title":"Structure\u2013activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins)","volume":"2","author":"Trapp","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2015.08.002_bib0570","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue \u03b1-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.phrs.2015.08.002_bib0575","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2014the development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0580","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0585","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0590","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.phrs.2015.08.002_bib0595","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2015.08.002_bib0600","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0605","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.phrs.2015.08.002_bib0610","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1093\/hmg\/dds379","article-title":"Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington\u2019s disease mice: implications for the ubiquitin-proteasomal and autophagy systems","volume":"21","author":"Jia","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2015.08.002_bib0615","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","article-title":"Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington\u2019s disease","volume":"94","author":"Zadori","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.phrs.2015.08.002_bib0620","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/hmg\/ddr552","article-title":"Long-term memory deficits in Huntington\u2019s disease are associated with reduced CBP histone acetylase activity","volume":"21","author":"Giralt","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2015.08.002_bib0625","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington\u2019s disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"26","key":"10.1016\/j.phrs.2015.08.002_bib0630","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1073\/pnas.261400698","article-title":"Histone deacetylase inhibitors reduce polyglutamine toxicity","volume":"98","author":"McCampbell","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.phrs.2015.08.002_bib0635","doi-asserted-by":"crossref","first-page":"13201","DOI":"10.1073\/pnas.191498198","article-title":"Altered transcription in yeast expressing expanded polyglutamine","volume":"98","author":"Hughes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"43","key":"10.1016\/j.phrs.2015.08.002_bib0640","doi-asserted-by":"crossref","first-page":"11174","DOI":"10.1523\/JNEUROSCI.3004-06.2006","article-title":"Mitochondrial-dependent Ca2+ handling in Huntington\u2019s disease striatal cells: effect of histone deacetylase inhibitors","volume":"26","author":"Oliveira","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2015.08.002_bib0645","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1073\/pnas.0737363100","article-title":"Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway","volume":"100","author":"Ryu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0650","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","article-title":"Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington\u2019s disease","volume":"41","author":"Hathorn","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2015.08.002_bib0655","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1523\/JNEUROSCI.3344-05.2006","article-title":"Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity","volume":"26","author":"Bates","year":"2006","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2015.08.002_bib0660","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1073\/pnas.1415195112","article-title":"HDAC inhibition imparts beneficial transgenerational effects in Huntington\u2019s disease mice via altered DNA and histone methylation","volume":"112","author":"Jia","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.08.002_bib0665","article-title":"Effects of pimelic diphenylamide histone deacetylase inhibitor HDACi 4b on the R6\/2 and N171-82Q Mouse models of Hungtington's disease","volume":"5","author":"Chen","year":"2013","journal-title":"PLoS curr."},{"issue":"9","key":"10.1016\/j.phrs.2015.08.002_bib0670","doi-asserted-by":"crossref","first-page":"e44498","DOI":"10.1371\/journal.pone.0044498","article-title":"Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in CNS Invivo","volume":"7","author":"Beconi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2015.08.002_bib0675","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1212\/WNL.27.2.193","article-title":"Long-term treatment of juvenile Huntington\u2019s chorea with dipropylacetic acid","volume":"27","author":"Bachman","year":"1977","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.phrs.2015.08.002_bib0680","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archneur.1977.00500170062012","article-title":"Valproate sodium in Huntington chorea","volume":"34","author":"Pearce","year":"1977","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.phrs.2015.08.002_bib0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-6-11","article-title":"Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington\u2019s disease patients: a case series","volume":"6","author":"Saft","year":"2006","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2015.08.002_bib0690","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/155005948001100202","article-title":"Myoclonic and major seizures in early adult Huntington\u2019s chorea: case-report and electro-clinical findings","volume":"11","author":"Kereshi","year":"1980","journal-title":"Clin. Electroencephalogr."},{"issue":"13","key":"10.1016\/j.phrs.2015.08.002_bib0695","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.08.002_bib0700","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1136\/jnnp-2012-303524.179","article-title":"Q09 Valproic Acid for the treatment of aggressiveness in Huntington\u2019s disease: 1-year follow-up","volume":"83","author":"Unti","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"13","key":"10.1016\/j.phrs.2015.08.002_bib0705","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.21632","article-title":"Sodium phenylbutyrate in Huntington\u2019s disease: a dose-finding study","volume":"22","author":"Hogarth","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2015.08.002_bib0710","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.drudis.2010.10.006","article-title":"Epigenetic therapies for non-oncology indications","volume":"15","author":"Best","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2015.08.002_bib0715","doi-asserted-by":"crossref","first-page":"A55","DOI":"10.1136\/jnnp-2012-303524.172","article-title":"Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients","volume":"83","author":"S\u00fcssmuth","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl. (10)","key":"10.1016\/j.phrs.2015.08.002_bib0720","article-title":"Safety and tolerability of selisistat for the treatment of Huntington\u2019s disease: results from a randomized, double-blind, placebo-controlled phase II trial (S47. 004)","volume":"82","author":"Reilmann","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2015.08.002_bib0725","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181500170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181500170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:33:08Z","timestamp":1718019188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181500170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":145,"alternative-id":["S104366181500170X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.08.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptional dysregulation in Huntington\u2019s disease: The role of histone deacetylases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}